Published in N Engl J Med on September 27, 1984
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Treating relentlessly progressive congestive heart failure: what next? Tex Heart Inst J (1998) 0.87
The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications. Heart Fail Rev (2011) 0.82
Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses. Heart (1997) 0.82
Contractile reserve assessed by dobutamine test identifies super-responders to cardiac resynchronization therapy. Arch Med Sci (2014) 0.81
Cardiac autonomic nervous system in heart failure: imaging technique and clinical implications. Curr Cardiol Rev (2011) 0.80
Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure. Br Heart J (1989) 0.78
Systems biology and biomechanical model of heart failure. Curr Cardiol Rev (2012) 0.78
Radionuclide imaging of cardiac sympathetic innervation in heart failure: unlocking untapped potential. Heart Fail Rev (2015) 0.77
Effects of early and late-onset treatment with carvedilol in an experimental model of aortic regurgitation. Springerplus (2015) 0.75
Dilated cardiomyopathy, myocarditis, and the bioptome. Br Med J (Clin Res Ed) (1986) 0.75
Evaluation of myocardial sympathetic innervation in the 21st century: Is there a role for planar (123)I-MIBG imaging? J Nucl Cardiol (2016) 0.75
Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. Heart Fail Rev (2004) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol (1995) 3.12
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet (1993) 3.10
Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res (2000) 3.08
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep (1978) 2.63
Congestive heart failure: fifty years of progress. Circulation (2000) 2.61
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med (1993) 2.39
Myosin heavy chain gene expression in human heart failure. J Clin Invest (1997) 2.39
Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant (1994) 2.36
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation (1996) 2.01
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation (1986) 1.97
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant (1990) 1.91
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest (1988) 1.85
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation (1997) 1.81
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol (2001) 1.70
Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep (1978) 1.68
Early anthracycline cardiotoxicity. Am J Med (1978) 1.63
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol (1998) 1.53
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol (1996) 1.52
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med (1992) 1.48
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med (2002) 1.47
Survival following cardiac transplantation--what are acceptable standards? West J Med (1987) 1.47
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol (2000) 1.43
Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation (1991) 1.43
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem (1996) 1.42
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation (1996) 1.41
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med (1978) 1.34
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med (1987) 1.34
Medicare-designated centers for cardiac transplantation. N Engl J Med (1987) 1.32
Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res (2001) 1.30
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation (1989) 1.29
Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J (1981) 1.27
Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation (1984) 1.21
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J (1983) 1.19
Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail (1998) 1.17
Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation (2001) 1.17
Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol (1985) 1.15
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest (1991) 1.12
Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol (1977) 1.10
Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep (1978) 1.10
Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol (1980) 1.09
Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol (1998) 1.09
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol (1999) 1.08
Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med (1990) 1.08
Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol (1990) 1.07
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J (1983) 1.07
New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail (1998) 1.07
Histamine and the human heart: the other receptor system. Am J Cardiol (1982) 1.07
Cardiac adrenergic receptor effects of carvedilol. Eur Heart J (1996) 1.06
Studies with isolated human coronary arteries. Some general observations, potential mediators of spasm, role of calcium antagonists. Chest (1980) 1.06
Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res (1989) 1.06
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer (1982) 1.04
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J (1981) 1.04
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail (1997) 1.02
Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest (1984) 1.01
Expression of alpha-subunits of G proteins in failing human heart: a reappraisal utilizing quantitative polymerase chain reaction. J Mol Cell Cardiol (1991) 1.01
Histamine receptors in the human heart. Life Sci (1980) 1.00
Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med (1983) 1.00
Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis (1984) 0.99
Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest (1983) 0.99
Echocardiographic evaluation of potential cardiac transplant donors. J Thorac Cardiovasc Surg (1988) 0.98
Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol (1982) 0.98
Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol (1985) 0.97
Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol (1985) 0.97
Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest (1981) 0.96
Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation (1990) 0.96
Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. J Thorac Cardiovasc Surg (1990) 0.95
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol (2000) 0.93
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol (2001) 0.93
Beta-adrenergic supersensitivity of the transplanted human heart is presynaptic in origin. Circulation (1989) 0.92
The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circ Res (1982) 0.92
Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol (1990) 0.91
Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology (1995) 0.91
beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol (1993) 0.91
Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant (1993) 0.91
Beta-adrenoceptor regulation in the human heart: can it be monitored in circulating lymphocytes? Eur Heart J (1989) 0.90
Tumor necrosis factor-alpha and cardiomyopathy. Circulation (1998) 0.90
Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J (1996) 0.90
Altered expression of alpha-subunits of G proteins in failing human hearts. J Mol Cell Cardiol (1989) 0.90
Myocardial beta-adrenergic receptor downregulation in heart failure. Int J Cardiol (1984) 0.90
Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation (1993) 0.90
Exercise capacity after heart transplantation: influence of donor and recipient characteristics. J Heart Lung Transplant (1996) 0.89
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination. Congest Heart Fail (2002) 0.89
Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc (1987) 0.88
Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. Ital Heart J (2001) 0.88
Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail (2000) 0.87
Histamine mediates myocardial damage by an H1 mechanism independent of coronary blood flow. J Cardiovasc Pharmacol (1990) 0.87
Histamine-mediated adenylate cyclase stimulation in human myocardium. Mol Pharmacol (1982) 0.87
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol (1999) 0.87
Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med (1986) 0.87